[Etiological mechanism of long QT syndrome and the effects of macrolides].
Kato
T
T
D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D027682:Cation Transport Proteins; D004268:DNA-Binding Proteins; D004347:Drug Interactions; D000072237:ERG1 Potassium Channel; D051638:Ether-A-Go-Go Potassium Channels; D006801:Humans; D051656:KCNQ Potassium Channels; D051657:KCNQ1 Potassium Channel; D008133:Long QT Syndrome / Q000209:etiology; D018942:Macrolides; D009154:Mutation; D026902:Potassium Channel Blockers; D015221:Potassium Channels / Q000235:genetics; D024642:Potassium Channels, Voltage-Gated; D016171:Torsades de Pointes / Q000209:etiology; D015534:Trans-Activators; D000071230:Transcriptional Regulator ERG; D014883:Water-Electrolyte Imbalance / Q000150:complications
D000900:Anti-Bacterial Agents; D027682:Cation Transport Proteins; D004268:DNA-Binding Proteins; C072312:ERG protein, human; D000072237:ERG1 Potassium Channel; D051638:Ether-A-Go-Go Potassium Channels; C092509:KCNH6 protein, human; D051656:KCNQ Potassium Channels; D051657:KCNQ1 Potassium Channel; C496909:KCNQ1 protein, human; D018942:Macrolides; D026902:Potassium Channel Blockers; D015221:Potassium Channels; D024642:Potassium Channels, Voltage-Gated; D015534:Trans-Activators; D000071230:Transcriptional Regulator ERG